|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Synergistic co-targeting of pro-apoptotic BAX and anti-apoptotic BCL-XL in cancer
|
1F31CA236434-01
|
$44,524
|
|
LOPEZ-ARROYO, ANDREA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel IL-15 Superagonist Therapy for Bladder Cancer
|
6R44CA156740-05
|
$999,919
|
|
RHODE, PETER
|
ALTOR BIOSCIENCE. LLC
|
|
Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays
|
1R43CA161965-01
|
$149,865
|
$37,466
|
Lim, Mark
|
AMBERGEN, INC
|
|
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
|
1R43CA236097-01
|
$300,000
|
|
LIM, MARK
|
AMBERGEN, INC
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S1
|
$2,000
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S2
|
$126,060
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Imaging and Radiation Oncology Core (IROC) Group
|
3U24CA180803-05S1
|
$335,460
|
|
FOLLOWILL, DAVID
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Integrative Oncology: From Research to Practical Applications
|
1R13CA236121-01
|
$5,000
|
|
RAO, SANTOSH
|
BANNER HEALTH
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer-associated fibroblast in the regulation of bladder cancer stem cells
|
3R01CA175397-05S1
|
$110,950
|
|
CHAN, KEITH SYSON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
3U54CA209978-03S1
|
$125,000
|
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Human natural killer cells: Advancing biology and clinical applications
|
7R35CA210087-02
|
$992,214
|
|
CALIGIURI, MICHAEL
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Impact of aging on the outcomes of a mouse model of chronic myeloid leukemia
|
4UH3CA213385-03
|
$87,498
|
|
CHEN, WENYONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$875
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Multifunctional immunoPET tracers for pancreatic and prostate cancer
|
7R01CA174294-06
|
$377,890
|
|
WU, ANNA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cytology-Free POC Cervical Cancer Diagnostics for Global Health
|
4UH3CA202663-03
|
$344,918
|
|
WEIDEMAIER, KRISTIN
|
BECTON, DICKINSON AND COMPANY
|
|
Parallel and high throughput isolation of cfDNA to target detection of rare, highly conserved nucleotide polymorphisms
|
1R43CA228923-01A1
|
$286,548
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Admin supplement - Chemical Approaches to Cell Signaling Enzymes
|
3R01CA074305-24S1
|
$73,513
|
|
COLE, PHILIP
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Pathogenesis and Treatment of NUT-Midline Carcinoma
|
3R01CA124633-11A1S1
|
$260,820
|
|
FRENCH, CHRISTOPHER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion
|
4UH3CA213392-03
|
$75,000
|
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Clinical Genome Resource
|
3U41HG006834-05S1
|
$75,000
|
|
REHM, HEIDI
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Role of melanoma-PD-1 in cancer progression: diversity supplement
|
3R01CA190838-02S1
|
$71,600
|
|
SCHATTON, TOBIAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR
|
4K00CA212229-03
|
$74,196
|
|
BONDESON, DANIEL
|
BROAD INSTITUTE, INC.
|
|
Promoting Physical Activity in Latinas via Interactive Web-based Technology
|
3R01CA159954-06S1
|
$228,636
|
|
MARCUS, BESS
|
BROWN UNIVERSITY
|
|
Investigating Fatty Acid Oxidation in Primary and Metastatic MYC-Overexpressing Triple-Negative Breast Cancer
|
4K00CA212488-03
|
$73,386
|
|
CAMARDA, ROMAN
|
BUCK INSTITUTE FOR RESEARCH ON AGING
|
|
Engineering Triggered Nanomechanical Therapeutics
|
5R01CA140759-03
|
$322,901
|
$96,870
|
PIERCE, NILES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer
|
3R44CA176937-03S1
|
$210,000
|
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
Treatment of glioblastoma using targeted nanoparticles
|
3U01CA198892-04S1
|
$66,200
|
|
COVARRUBIAS, GIL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting TCA cycle in Brain Tumor Initiating Cells
|
5F30CA203101-04
|
$44,524
|
|
KIM, JIN YOUNG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Novel Bi-functional Inhibitors Blocking OncomiR Biogenesis
|
7R21CA202831-04
|
$229,837
|
|
LIANG, FU-SEN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cancer Initiating Cells and Treatment Resistance
|
7R01CA193590-04
|
$368,551
|
|
PAN, QUINTIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
The Unfolded Protein Response in Glioblastoma
|
5F30CA217066-03
|
$47,683
|
|
PRAGER, BRIANA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
3R01CA177069-05S1
|
$75,000
|
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
3R01CA211707-02S1
|
$149,945
|
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
|
Investigation and functional characterization of new drivers of mesenchymal tumorigenesis.
|
4R00CA212200-03
|
$249,000
|
|
GUARNERIO, JLENIA
|
CEDARS-SINAI MEDICAL CENTER
|
Total relevant funding to Autoimmune Diseases for this search: $11,553,939
|